^
Association details:
| Biomarker: | IDH2 R172K |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Xpovio (selinexor) (XPO1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IDH2 P.R172K MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) MAY BE ASSOCIATED WITH FAVORABLE RESPONSE TO SELINEXOR TREATMENT
Published date:
05/14/2020
Excerpt:
To identify mutations associated with selinexor response,…Median overall survival of the IDH2 p.R172K patients was 11.60 months (locked data range: 3.78-17.51 months), compared to 2.43 months in patients without this mutation.
Trial ID:
